The cell cycle coming under control.
An article in 30 June issue (";Dangerous' liaisons in cell biology," p. 1539), which discussed the commentary in the 2 June issue of the journal Cell by Max L. Birnstiel and Meinrad Busslinger regarding the transgenic mice experiments of Corrado Spadafora and co-workers, stated that Vienna's Institute of Molecular Pathology (IMP), for which Birnstiel and Busslinger work, was seeking patents on extensions of the Spadafora experiments. On further investigation, we have learned that this is not correct. At present no applications have been applied for or granted to IMP or its parent companies Genentech and Boehringer Ingelheim. We wish to correct the record, apologize to Dr. Birnstiel and Dr. Busslinger for this misstatement, and alert our readers to their letter, which is printed in our Letters section on page 243.